Sign up USA
Proactive Investors - Run By Investors For Investors

Aimmune Therapeutics shares bolstered while DBV Technologies' plunges on peanut allergy treatment trial findings

Aimmune Therapeutics shares bolstered while DBV Technologies' plunges on peanut allergy treatment trial findings
Aimmune Therapeutics shares bolstered while DBV Technologies' plunges on peanut allergy treatment trial findings
Not everyone can tolerate peanuts out there

Shares in Aimmune Therapeutics (NASDAQ:AIMT) raced up nearly 30% in New York on Monday in response to the announcement from DBV Technologies' (NASDAQ:DBVT) over its peanut allergy treatment.

Meanwhile, shares in the latter plunged over 46% to US$26.21 to be the worst performer on Nasdaq on Monday. Aimmune Therapeutics on the other hand raced up to US$33.23 each.

Viaskin Peanut,  the DBV treatment, reportedly failed to demonstrate sufficient efficacy in a pivotal phase III trial.

The trial was evaluating the safety and efficacy of Viaskin Peanut in children four to 11 years.

Topline results showed a statistically significant response with a favorable tolerability profile, with 35.3% of patients responding to Viaskin Peanut 250 µg after 12 months of treatment as compared to 13.6% of patients in the placebo arm.

However, the primary endpoint did not reach the point as had been proposed in the study's Statistical Analysis Plan (SAP) submitted to the US FDA.

Aimmune's lead candidate is an orally administered biologic that desensitizes patients with peanut allergy.

A Phase 3 study, PALISADE, is ongoing with an estimated completion date of September 2018.

View full PROAC profile View Profile

Proactiveinvestors Timeline

Related Articles

August 15 2018
Milan Patel, dotdigital’s chief executive officer said: "This year reflects substantial progress against the company's strategic aims in accelerating our platform capabilities into the omnichannel space, continuing to innovate our product, growing geographically and deepening our relationships with our strategic partners”
Media junkie
February 13 2018
In modern parlance, Ebiquity is making a pivot towards becoming the "world's leading tech-enabled marketing and media analytics consultancy"
Throne of Glass
April 30 2018
Rowling, Rowling, Rowling ... keep those titles rolling. Mind you, it's not all about Ms Rowling; Sarah J Maas title revenues grew 47% in the first half of the financial year and dieters are gorging on Tom Kerridge's books

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright ©, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use